SPECTRILA 10000 U Price

Overview

Welcome to Dwaey, specifically on SPECTRILA 10000 U Infusion/Powder for concentrate for solution for page.
This medicine contains an important and useful components, as it consists of Asparaginase.
SPECTRILA 10000 U is available in the market in concentration 10000 Unit /Vial and in the form of Infusion/Powder for concentrate for solution for.

MEDAC GmbH is the producer of SPECTRILA 10000 U and it is imported from GERMANY, The most popular alternatives of SPECTRILA 10000 U are listed downward .

Mode Of Action

Asparaginase interferes with malignant cell growth by breaking down asparagine to aspartic acid and ammonia as leukemic cells are unable to synthesise asparagine and depends on exogenous source of asparagine for survival. It acts on the G1 phase of the cell cycle.

Indication

• Acute Lymphocytic Leukemia

Precaution

Should be used after skin testing, in hospital setting. Liver disease, frequently blood count monitoring. Lactation. Lactation: It is not known whether this drug is excreted in milk. Because of the potential for serious adverse reactions in nursing infants from Elspar, a decision should be made to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Side Effects

• >10% Abdominal cramps (70%)
• Anorexia (70%)
• Azotemia (66%)
• Nausea (50-60%)
• Vomiting (50-60%)
• Agitation (10-60%)
• Depression (10-60%)
• Fatigue (10-60%)
• Fever (10-60%)
• Chills (10-60%)
• Anaphylaxis (15-35%)
• Coma (25%)
• Confusion (25%)
• Somnolence (25%)
• Stupor (25%)
• Pancreatitis
• acute (15%) 1-10% Hyperglycemia
• Stomatitis
• Hyperuricemia <1% Disorientation
• Drowsiness
• Hallucination
• Headache
• Hyperthermia
• Parkinsonian symptoms
• Venous thrombosis
• Hypotension
• Intracranial hemorrhage
• Cerebrovascular hemorrhage
• Peripheral edema
• Thrombosis
• Cough
• Hypofibrinogenemia
• Depression of clotting factors
• Severe protein C deficiency
• Decrease antithrombin III
• Glucosuria
• Hemorrhagic pancreatitis
• Ketoacidosis
• Hepatotoxicity
• Urticaria
• Weight loss
• Acute renal failure

Contra indication

Hypersensitivity. History of pancreatitis, thrombosis, or serious pancreatitis events with prior L-asparaginase treatment.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks